Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 36 entries
Sorted by: Best Match Show Resources per page
Sphingosine 1-Phosphate Receptors: Do They Have a Therapeutic Potential in Cardiac Fibrosis?.

Frontiers in pharmacology

Vestri A, Pierucci F, Frati A, Monaco L, Meacci E.
PMID: 28626422
Front Pharmacol. 2017 Jun 02;8:296. doi: 10.3389/fphar.2017.00296. eCollection 2017.

Sphingosine 1-phosphate (S1P) is a bioactive lipid that is characterized by a peculiar mechanism of action. In fact, S1P, which is produced inside the cell, can act as an intracellular mediator, whereas after its export outside the cell, it...

Cite
Vestri A, Pierucci F, Frati A, et al. Sphingosine 1-Phosphate Receptors: Do They Have a Therapeutic Potential in Cardiac Fibrosis?. Front Pharmacol. 2017;8:296doi: 10.3389/fphar.2017.00296.
Vestri, A., Pierucci, F., Frati, A., Monaco, L., & Meacci, E. (2017). Sphingosine 1-Phosphate Receptors: Do They Have a Therapeutic Potential in Cardiac Fibrosis?. Frontiers in pharmacology, 8296. https://doi.org/10.3389/fphar.2017.00296
Vestri, Ambra, et al. "Sphingosine 1-Phosphate Receptors: Do They Have a Therapeutic Potential in Cardiac Fibrosis?." Frontiers in pharmacology vol. 8 (2017): 296. doi: https://doi.org/10.3389/fphar.2017.00296
Vestri A, Pierucci F, Frati A, Monaco L, Meacci E. Sphingosine 1-Phosphate Receptors: Do They Have a Therapeutic Potential in Cardiac Fibrosis?. Front Pharmacol. 2017 Jun 02;8:296. doi: 10.3389/fphar.2017.00296. eCollection 2017. PMID: 28626422; PMCID: PMC5454082.
Copy Download .nbib Format: NLM
Life-threatening asthma attack during prolonged fingolimod treatment: case report.

Patient preference and adherence

Zecca C, Caporro M, Györik S, Gobbi C.
PMID: 25053881
Patient Prefer Adherence. 2014 Jul 14;8:987-9. doi: 10.2147/PPA.S65708. eCollection 2014.

BACKGROUND: Fingolimod (FTY) mediates bronchoconstriction by interacting with sphingosine-1-phosphate receptors. The majority of the reported adverse respiratory events occur during the first weeks of treatment.CASE PRESENTATION: A 49-year-old woman developed a life-threatening asthma attack after 6 months of continuous...

Cite
Zecca C, Caporro M, Györik S, et al. Life-threatening asthma attack during prolonged fingolimod treatment: case report. Patient Prefer Adherence. 2014;8:987-9doi: 10.2147/PPA.S65708.
Zecca, C., Caporro, M., Györik, S., & Gobbi, C. (2014). Life-threatening asthma attack during prolonged fingolimod treatment: case report. Patient preference and adherence, 8987-9. https://doi.org/10.2147/PPA.S65708
Zecca, Chiara, et al. "Life-threatening asthma attack during prolonged fingolimod treatment: case report." Patient preference and adherence vol. 8 (2014): 987-9. doi: https://doi.org/10.2147/PPA.S65708
Zecca C, Caporro M, Györik S, Gobbi C. Life-threatening asthma attack during prolonged fingolimod treatment: case report. Patient Prefer Adherence. 2014 Jul 14;8:987-9. doi: 10.2147/PPA.S65708. eCollection 2014. PMID: 25053881; PMCID: PMC4105229.
Copy Download .nbib Format: NLM
Immunohistochemical analysis indicates that the anatomical location of B-cell non-Hodgkin's lymphoma is determined by differentially expressed chemokine receptors, sphingosine-1-phosphate receptors and integrins.

Experimental hematology & oncology

Middle S, Coupland SE, Taktak A, Kidgell V, Slupsky JR, Pettitt AR, Till KJ.
PMID: 25938000
Exp Hematol Oncol. 2015 Apr 01;4:10. doi: 10.1186/s40164-015-0004-3. eCollection 2015.

BACKGROUND: The aim of this study was to elucidate the mechanisms responsible for the location of B-cell non-Hodgkin's lymphoma (B-NHL) at different anatomical sites. We speculated that the malignant B cells in these disorders have the potential for trafficking...

Cite
Middle S, Coupland SE, Taktak A, et al. Immunohistochemical analysis indicates that the anatomical location of B-cell non-Hodgkin's lymphoma is determined by differentially expressed chemokine receptors, sphingosine-1-phosphate receptors and integrins. Exp Hematol Oncol. 2015;4:10doi: 10.1186/s40164-015-0004-3.
Middle, S., Coupland, S. E., Taktak, A., Kidgell, V., Slupsky, J. R., Pettitt, A. R., & Till, K. J. (2015). Immunohistochemical analysis indicates that the anatomical location of B-cell non-Hodgkin's lymphoma is determined by differentially expressed chemokine receptors, sphingosine-1-phosphate receptors and integrins. Experimental hematology & oncology, 410. https://doi.org/10.1186/s40164-015-0004-3
Middle, Stephen, et al. "Immunohistochemical analysis indicates that the anatomical location of B-cell non-Hodgkin's lymphoma is determined by differentially expressed chemokine receptors, sphingosine-1-phosphate receptors and integrins." Experimental hematology & oncology vol. 4 (2015): 10. doi: https://doi.org/10.1186/s40164-015-0004-3
Middle S, Coupland SE, Taktak A, Kidgell V, Slupsky JR, Pettitt AR, Till KJ. Immunohistochemical analysis indicates that the anatomical location of B-cell non-Hodgkin's lymphoma is determined by differentially expressed chemokine receptors, sphingosine-1-phosphate receptors and integrins. Exp Hematol Oncol. 2015 Apr 01;4:10. doi: 10.1186/s40164-015-0004-3. eCollection 2015. PMID: 25938000; PMCID: PMC4416323.
Copy Download .nbib Format: NLM
Cardiac Safety Profile of First Dose of Fingolimod for Relapsing-Remitting Multiple Sclerosis in Real-World Settings: Data from a German Prospective Multi-Center Observational Study.

Neurology and therapy

Linker RA, Wendt G.
PMID: 27624575
Neurol Ther. 2016 Dec;5(2):193-201. doi: 10.1007/s40120-016-0051-7. Epub 2016 Sep 13.

INTRODUCTION: Fingolimod was the first oral therapy approved for the treatment of relapsing-remitting multiple sclerosis (RRMS). Due to its action on cardiac sphingosine 1-phosphate receptors, fingolimod is leading to a transient decrease in heart rate (HR) and the occurrence...

Cite
Linker RA, Wendt G. Cardiac Safety Profile of First Dose of Fingolimod for Relapsing-Remitting Multiple Sclerosis in Real-World Settings: Data from a German Prospective Multi-Center Observational Study. Neurol Ther. 2016;5(2):193-201doi: 10.1007/s40120-016-0051-7.
Linker, R. A., & Wendt, G. (2016). Cardiac Safety Profile of First Dose of Fingolimod for Relapsing-Remitting Multiple Sclerosis in Real-World Settings: Data from a German Prospective Multi-Center Observational Study. Neurology and therapy, 5(2), 193-201. https://doi.org/10.1007/s40120-016-0051-7
Linker, Ralf A, and Wendt, Guillaume. "Cardiac Safety Profile of First Dose of Fingolimod for Relapsing-Remitting Multiple Sclerosis in Real-World Settings: Data from a German Prospective Multi-Center Observational Study." Neurology and therapy vol. 5,2 (2016): 193-201. doi: https://doi.org/10.1007/s40120-016-0051-7
Linker RA, Wendt G. Cardiac Safety Profile of First Dose of Fingolimod for Relapsing-Remitting Multiple Sclerosis in Real-World Settings: Data from a German Prospective Multi-Center Observational Study. Neurol Ther. 2016 Dec;5(2):193-201. doi: 10.1007/s40120-016-0051-7. Epub 2016 Sep 13. PMID: 27624575; PMCID: PMC5130918.
Copy Download .nbib Format: NLM
Sphingosine Kinases and Sphingosine 1-Phosphate Receptors: Signaling and Actions in the Cardiovascular System.

Frontiers in pharmacology

Cannavo A, Liccardo D, Komici K, Corbi G, de Lucia C, Femminella GD, Elia A, Bencivenga L, Ferrara N, Koch WJ, Paolocci N, Rengo G.
PMID: 28878674
Front Pharmacol. 2017 Aug 23;8:556. doi: 10.3389/fphar.2017.00556. eCollection 2017.

The sphingosine kinases 1 and 2 (SphK1 and 2) catalyze the phosphorylation of the lipid, sphingosine, generating the signal transmitter, sphingosine 1-phosphate (S1P). The activation of such kinases and the subsequent S1P generation and secretion in the blood serum...

Cite
Cannavo A, Liccardo D, Komici K, et al. Sphingosine Kinases and Sphingosine 1-Phosphate Receptors: Signaling and Actions in the Cardiovascular System. Front Pharmacol. 2017;8:556doi: 10.3389/fphar.2017.00556.
Cannavo, A., Liccardo, D., Komici, K., Corbi, G., de Lucia, C., Femminella, G. D., Elia, A., Bencivenga, L., Ferrara, N., Koch, W. J., Paolocci, N., & Rengo, G. (2017). Sphingosine Kinases and Sphingosine 1-Phosphate Receptors: Signaling and Actions in the Cardiovascular System. Frontiers in pharmacology, 8556. https://doi.org/10.3389/fphar.2017.00556
Cannavo, Alessandro, et al. "Sphingosine Kinases and Sphingosine 1-Phosphate Receptors: Signaling and Actions in the Cardiovascular System." Frontiers in pharmacology vol. 8 (2017): 556. doi: https://doi.org/10.3389/fphar.2017.00556
Cannavo A, Liccardo D, Komici K, Corbi G, de Lucia C, Femminella GD, Elia A, Bencivenga L, Ferrara N, Koch WJ, Paolocci N, Rengo G. Sphingosine Kinases and Sphingosine 1-Phosphate Receptors: Signaling and Actions in the Cardiovascular System. Front Pharmacol. 2017 Aug 23;8:556. doi: 10.3389/fphar.2017.00556. eCollection 2017. PMID: 28878674; PMCID: PMC5572949.
Copy Download .nbib Format: NLM
Identification of key genes of human bone marrow stromal cells adipogenesis at an early stage.

PeerJ

Chen P, Song M, Wang Y, Deng S, Hong W, Zhang X, Yu B.
PMID: 32742785
PeerJ. 2020 Jul 21;8:e9484. doi: 10.7717/peerj.9484. eCollection 2020.

BACKGROUND: Bone marrow adipocyte (BMA), closely associated with bone degeneration, shares common progenitors with osteoblastic lineage. However, the intrinsic mechanism of cells fate commitment between BMA and osteogenic lineage remains unclear.METHODS: Gene Expression Omnibus (GEO) dataset GSE107789 publicly available...

Cite
Chen P, Song M, Wang Y, et al. Identification of key genes of human bone marrow stromal cells adipogenesis at an early stage. PeerJ. 2020;8:e9484doi: 10.7717/peerj.9484.
Chen, P., Song, M., Wang, Y., Deng, S., Hong, W., Zhang, X., & Yu, B. (2020). Identification of key genes of human bone marrow stromal cells adipogenesis at an early stage. PeerJ, 8e9484. https://doi.org/10.7717/peerj.9484
Chen, Pengyu, et al. "Identification of key genes of human bone marrow stromal cells adipogenesis at an early stage." PeerJ vol. 8 (2020): e9484. doi: https://doi.org/10.7717/peerj.9484
Chen P, Song M, Wang Y, Deng S, Hong W, Zhang X, Yu B. Identification of key genes of human bone marrow stromal cells adipogenesis at an early stage. PeerJ. 2020 Jul 21;8:e9484. doi: 10.7717/peerj.9484. eCollection 2020. PMID: 32742785; PMCID: PMC7380279.
Copy Download .nbib Format: NLM
Blood-thirsty: S1PR5 and TRM.

The Journal of experimental medicine

Hallisey VM, Schwab SR.
PMID: 34714328
J Exp Med. 2022 Jan 03;219(1). doi: 10.1084/jem.20211971. Epub 2021 Oct 29.

In this elegant study, Evrard et al. (2021. J. Exp. Med.https://doi.org/10.1084/jem.20210116) find that sphingosine 1-phosphate receptor 5 (S1PR5) powerfully impairs tissue-resident memory T cell (TRM) formation, and that tissue-derived TGF-β limits S1pr5 expression by infiltrating T cells.

Cite
Hallisey VM, Schwab SR. Blood-thirsty: S1PR5 and TRM. J Exp Med. 2021;219(1)doi: 10.1084/jem.20211971.
Hallisey, V. M., & Schwab, S. R. (2022). Blood-thirsty: S1PR5 and TRM. The Journal of experimental medicine, 219(1), . https://doi.org/10.1084/jem.20211971
Hallisey, Victoria M, and Schwab, Susan R. "Blood-thirsty: S1PR5 and TRM." The Journal of experimental medicine vol. 219,1 (2022). doi: https://doi.org/10.1084/jem.20211971
Hallisey VM, Schwab SR. Blood-thirsty: S1PR5 and TRM. J Exp Med. 2022 Jan 03;219(1). doi: 10.1084/jem.20211971. Epub 2021 Oct 29. PMID: 34714328; PMCID: PMC8574975.
Copy Download .nbib Format: NLM
Evaluation of S1PR1, pSTAT3, S1PR2, FOXP1 Expression in Aggressive, Mature B Cell Lymphomas.

Journal of hematopathology

Al-Kawaaz M, Sanchez T, Kluk MJ.
PMID: 31404445
J Hematop. 2019 Jun;12(2):57-65. doi: 10.1007/s12308-019-00354-y. Epub 2019 Apr 27.

BACKGROUND: Aggressive, mature B-cell lymphomas include Burkitt Lymphoma (BL), High Grade B Cell Lymphomas (HGBL) (eg, Double-Hit B cell lymphomas (HGBL-DH: HGBL with MYC and BCL2 and/or BCL6 translocations)), HGBL, Not Otherwise Specified (HGBL, NOS) and Diffuse Large B...

Cite
Al-Kawaaz M, Sanchez T, Kluk MJ. Evaluation of S1PR1, pSTAT3, S1PR2, FOXP1 Expression in Aggressive, Mature B Cell Lymphomas. J Hematop. 2019;12(2):57-65doi: 10.1007/s12308-019-00354-y.
Al-Kawaaz, M., Sanchez, T., & Kluk, M. J. (2019). Evaluation of S1PR1, pSTAT3, S1PR2, FOXP1 Expression in Aggressive, Mature B Cell Lymphomas. Journal of hematopathology, 12(2), 57-65. https://doi.org/10.1007/s12308-019-00354-y
Al-Kawaaz, Mustafa, et al. "Evaluation of S1PR1, pSTAT3, S1PR2, FOXP1 Expression in Aggressive, Mature B Cell Lymphomas." Journal of hematopathology vol. 12,2 (2019): 57-65. doi: https://doi.org/10.1007/s12308-019-00354-y
Al-Kawaaz M, Sanchez T, Kluk MJ. Evaluation of S1PR1, pSTAT3, S1PR2, FOXP1 Expression in Aggressive, Mature B Cell Lymphomas. J Hematop. 2019 Jun;12(2):57-65. doi: 10.1007/s12308-019-00354-y. Epub 2019 Apr 27. PMID: 31404445; PMCID: PMC6688509.
Copy Download .nbib Format: NLM
Sphingosine 1-phosphate receptors and sphingosine kinase 1: novel biomarkers for clinical prognosis in breast, prostate, and hematological cancers.

Frontiers in oncology

Pyne S, Edwards J, Ohotski J, Pyne NJ.
PMID: 23316473
Front Oncol. 2012 Dec 03;2:168. doi: 10.3389/fonc.2012.00168. eCollection 2012.

There is substantial evidence for a role in cancer of the bioactive lipid sphingosine 1-phosphate (S1P), the enzyme sphingosine kinase 1 (that catalyses S1P formation) and S1P-specific G protein-coupled receptors. This perspective highlights recent findings demonstrating that sphingosine kinase...

Cite
Pyne S, Edwards J, Ohotski J, et al. Sphingosine 1-phosphate receptors and sphingosine kinase 1: novel biomarkers for clinical prognosis in breast, prostate, and hematological cancers. Front Oncol. 2012;2:168doi: 10.3389/fonc.2012.00168.
Pyne, S., Edwards, J., Ohotski, J., & Pyne, N. J. (2012). Sphingosine 1-phosphate receptors and sphingosine kinase 1: novel biomarkers for clinical prognosis in breast, prostate, and hematological cancers. Frontiers in oncology, 2168. https://doi.org/10.3389/fonc.2012.00168
Pyne, Susan, et al. "Sphingosine 1-phosphate receptors and sphingosine kinase 1: novel biomarkers for clinical prognosis in breast, prostate, and hematological cancers." Frontiers in oncology vol. 2 (2012): 168. doi: https://doi.org/10.3389/fonc.2012.00168
Pyne S, Edwards J, Ohotski J, Pyne NJ. Sphingosine 1-phosphate receptors and sphingosine kinase 1: novel biomarkers for clinical prognosis in breast, prostate, and hematological cancers. Front Oncol. 2012 Dec 03;2:168. doi: 10.3389/fonc.2012.00168. eCollection 2012. PMID: 23316473; PMCID: PMC3540928.
Copy Download .nbib Format: NLM
The novel sphingosine-1-phosphate receptors antagonist AD2900 affects lymphocyte activation and inhibits T-cell entry into the lymph nodes.

Oncotarget

Song J, Dagan A, Yakhtin Z, Gatt S, Riley S, Rosen H, Or R, Almogi-Hazan O.
PMID: 28881832
Oncotarget. 2017 Jun 27;8(32):53563-53580. doi: 10.18632/oncotarget.18626. eCollection 2017 Aug 08.

Sphingolipid derivatives play key roles in immune cell migration and function. Synthetic sphingolipid analogues are used as therapeutics to intervene various inflammatory and malignant conditions. We hypothesize that different analogs have different effects on immune cells and therefore can...

Cite
Song J, Dagan A, Yakhtin Z, et al. The novel sphingosine-1-phosphate receptors antagonist AD2900 affects lymphocyte activation and inhibits T-cell entry into the lymph nodes. Oncotarget. 2017;8(32):53563-53580doi: 10.18632/oncotarget.18626.
Song, J., Dagan, A., Yakhtin, Z., Gatt, S., Riley, S., Rosen, H., Or, R., & Almogi-Hazan, O. (2017). The novel sphingosine-1-phosphate receptors antagonist AD2900 affects lymphocyte activation and inhibits T-cell entry into the lymph nodes. Oncotarget, 8(32), 53563-53580. https://doi.org/10.18632/oncotarget.18626
Song, Jing, et al. "The novel sphingosine-1-phosphate receptors antagonist AD2900 affects lymphocyte activation and inhibits T-cell entry into the lymph nodes." Oncotarget vol. 8,32 (2017): 53563-53580. doi: https://doi.org/10.18632/oncotarget.18626
Song J, Dagan A, Yakhtin Z, Gatt S, Riley S, Rosen H, Or R, Almogi-Hazan O. The novel sphingosine-1-phosphate receptors antagonist AD2900 affects lymphocyte activation and inhibits T-cell entry into the lymph nodes. Oncotarget. 2017 Jun 27;8(32):53563-53580. doi: 10.18632/oncotarget.18626. eCollection 2017 Aug 08. PMID: 28881832; PMCID: PMC5581131.
Copy Download .nbib Format: NLM
Blood-thirsty: S1PR5 and TRM.

The Journal of experimental medicine

Hallisey VM, Schwab SR.
PMID: 34714328
J Exp Med. 2022 Jan 03;219(1). doi: 10.1084/jem.20211971. Epub 2021 Oct 29.

In this elegant study, Evrard et al. (2021. J. Exp. Med.https://doi.org/10.1084/jem.20210116) find that sphingosine 1-phosphate receptor 5 (S1PR5) powerfully impairs tissue-resident memory T cell (TRM) formation, and that tissue-derived TGF-β limits S1pr5 expression by infiltrating T cells.

Cite
Hallisey VM, Schwab SR. Blood-thirsty: S1PR5 and TRM. J Exp Med. 2021;219(1)doi: 10.1084/jem.20211971.
Hallisey, V. M., & Schwab, S. R. (2022). Blood-thirsty: S1PR5 and TRM. The Journal of experimental medicine, 219(1), . https://doi.org/10.1084/jem.20211971
Hallisey, Victoria M, and Schwab, Susan R. "Blood-thirsty: S1PR5 and TRM." The Journal of experimental medicine vol. 219,1 (2022). doi: https://doi.org/10.1084/jem.20211971
Hallisey VM, Schwab SR. Blood-thirsty: S1PR5 and TRM. J Exp Med. 2022 Jan 03;219(1). doi: 10.1084/jem.20211971. Epub 2021 Oct 29. PMID: 34714328; PMCID: PMC8574975.
Copy Download .nbib Format: NLM
Sphingosine-1-Phosphate Receptors Modulators Decrease Signs of Neuroinflammation and Prevent Parkinson's Disease Symptoms in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model.

Frontiers in pharmacology

Pépin É, Jalinier T, Lemieux GL, Massicotte G, Cyr M.
PMID: 32153401
Front Pharmacol. 2020 Feb 21;11:77. doi: 10.3389/fphar.2020.00077. eCollection 2020.

Sphingosine-1-phosphate (S1P) is a potent bioactive lipid mediator that acts as a natural ligand upon binding to five different receptors that are located in astrocytes, oligodendrocytes, microglial and neuronal cells. Recently, global activation of these receptors by FTY720 (fingolimod)...

Cite
Pépin É, Jalinier T, Lemieux GL, et al. Sphingosine-1-Phosphate Receptors Modulators Decrease Signs of Neuroinflammation and Prevent Parkinson's Disease Symptoms in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model. Front Pharmacol. 2020;11:77doi: 10.3389/fphar.2020.00077.
Pépin, �. �., Jalinier, T., Lemieux, G. L., Massicotte, G., & Cyr, M. (2020). Sphingosine-1-Phosphate Receptors Modulators Decrease Signs of Neuroinflammation and Prevent Parkinson's Disease Symptoms in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model. Frontiers in pharmacology, 1177. https://doi.org/10.3389/fphar.2020.00077
Pépin, Élise, et al. "Sphingosine-1-Phosphate Receptors Modulators Decrease Signs of Neuroinflammation and Prevent Parkinson's Disease Symptoms in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model." Frontiers in pharmacology vol. 11 (2020): 77. doi: https://doi.org/10.3389/fphar.2020.00077
Pépin É, Jalinier T, Lemieux GL, Massicotte G, Cyr M. Sphingosine-1-Phosphate Receptors Modulators Decrease Signs of Neuroinflammation and Prevent Parkinson's Disease Symptoms in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model. Front Pharmacol. 2020 Feb 21;11:77. doi: 10.3389/fphar.2020.00077. eCollection 2020. PMID: 32153401; PMCID: PMC7047735.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 36 entries